Skip to content

Veeva Systems

US · VEEV #470 by market cap Listed 1970
266.22 +3.30 +1.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Fair Value how this is computed

Near fair value
244.01 fair value ≈ 324.20 404.39
  • Implied fair-value range of 244.01-404.39, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -17.9% below the average-multiple fair value of 324.20.

Valuation each multiple against its own 5-year range

P/B ratio 5.80 Cheap vs history 16th percentile
5-year average 7.44 · #31 of 37 in Health Information Services
P/E ratio 43.64 Cheap vs history 14th percentile
5-year average 59.60 · forward 37.67 · #10 of 16 in Health Information Services
P/S ratio 12.46 Cheap vs history 24th percentile
5-year average 13.95 · forward 11.04 · #37 of 41 in Health Information Services

Vs. peers Health Information Services

Company Market cap P/E (TTM) P/B Div yield
Veeva Systems (VEEV) 43.10B 43.64 5.80 0.00%
BrightSpring Health Services (BTSG) 12.50B 33.78 5.75 0.00%
Tempus AI (TEM) 9.86B -50.98 19.70 0.00%
Hinge Health (HNGE) 8.60B 51.68 28.71 0.00%
HealthEquity (HQY) 7.84B 34.21 3.94 0.00%
Doximity (DOCS) 5.13B 39.90 5.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value300.44 Economic moatWide UncertaintyLow Capital allocationExemplary

Trading 12.9% below Morningstar's fair value estimate.

Analyst note

Veeva hosted its annual investor day on Nov. 5 where it discussed its artificial intelligence platform, product strategy, and long-term financial targets. Shares are down 2% intraday Nov. 6.

Why it matters: We appreciated hearing more thoughts on not just Veeva's AI ambition but also the firm's pricing strategy. Veeva AI currently breaks down into two main products: Vault AI and Falcon. Vault AI looks like a chatbot with some interesting features, similar to agents we see in other websites or applications. We like that it can access Vault data, which should add to its selling point, is customizable, and comes with predictable pricing at 10% of the annual Vault subscription fee. This is unique from other agents that are typically priced based on consumption. Falcon AI, as we called out previously, looks to us as a bigger opportunity for Veeva since it can actually do the work rather than simply assist end users. Though still in the early days, Falcon looks like a feature that could differentiate Veeva from peers like Salesforce/IQVIA and other AI firms. It is priced at a flat annual license fee with the price dependent on customer size.

The bottom line: We maintain our $287 per share fair value estimate for wide-moat Veeva. Overall, we thought the investor day didn't introduce anything new or groundbreaking but rather painted a clearer picture on Veeva's strategy on both AI investments and organic growth. We think it's important for investors that Veeva clearly lays out how AI can benefit the firm's competitive advantage and the safety of its moat, and we come away from the investor day with a more favorable outlook on its AI strategy. The 2030 revenue target of $6 billion, first announced at the 2024 investor day, was reiterated, but this does not depend on Falcon or Vault AI. This tells us that Veeva is still very much in the early days of AI implementation and commercialization, which is fine since we think winning in the long term is more important.

Fair value

Veeva Systems Inc is assigned a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 12% discount to our quantitative fair value estimate of $300.44 per share, which is reinforced by this estimate's low uncertainty rating.

The company's balance sheet bolsters our quantitative valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's debt to EBITDA ratio of 0.1 ranks in the bottom 10% compared with global peers. Without much debt relative to assets, this company should exhibit high resilience should the global economy weaken; if not, the company could raise debt and invest in the business or return capital to shareholders. We believe this is a sign that shares could be undervalued.

On a different note, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 6.9%, for example, falls in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

The company's wide quantitative moat rating suggests a strong ability to maintain superior profitability thanks to competitive advantages that could persist up to two decades. This is supported by the company's strong financial health score, which indicates a low likelihood that the company will tumble into financial distress.

Bull case

Veeva continues to introduce new applications in areas such as safety and clinical operations to service unmet needs, which support our double-digit growth assumptions.

Investing in its AI capabilities allows Veeva to provide additional services, deploy advanced technologies, and bolster switching costs.

Venturing outside of life sciences and into new segments expands Veeva’s end markets and opens up new opportunities.

Bear case

Moving its CRM from Salesforce’s platform to its Vault Platform could raise concerns for customers and lower its retention rate.

The Iqvia/Salesforce partnership to introduce its own version of life sciences CRM could take away potential new customers from Veeva.

New modules or add-ons could show low penetration rate and win less customers compared with previously launched products.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.

Veeva Systems discussion 0 comments

Add a comment